THE APEX TIMES
The move follows a third-quarter beat and Piper Sandler’s decision to raise its outlook, tying the higher valuation to Moderna’s collaboration with Merck on a melanoma vaccine.
Moderna shares rose for a second straight session, jumping about 9% after Piper Sandler raised its price target to $305 from $230. The broker’s change came in the wake of Moderna’s third-quarter results, which Piper characterized as a beat.
In the note driving the stock reaction, Piper’s higher target reflects what the broker sees as improving prospects for Moderna’s pipeline, with particular emphasis on a melanoma vaccine program being developed in collaboration with Merck.
The melanoma vaccine, as described in market coverage of the broker action, is a key part of the valuation debate for Moderna. Piper’s revised target suggests it believes the program’s commercial and clinical trajectory is progressing better than previously expected.
The stock move highlights how sensitive Moderna’s shares can be to Wall Street expectations for late-stage development and near-term execution. Even without additional detail in the coverage about trial milestones, the broker’s raised outlook indicates confidence is increasing around program timing or the likelihood of favorable outcomes.
The company is widely viewed as a platform-driven biotech, but its investor narrative has often narrowed to specific assets and whether they can translate into meaningful product timelines. In this case, the focus is squarely on the melanoma vaccine effort tied to Merck.
For readers tracking Moderna, the practical takeaway is that at least one major analyst is anchoring its higher valuation on the melanoma collaboration rather than broad-based optimism alone. That framing implies that future analyst notes, and subsequent market moves, may continue to hinge on updates related to development progress and regulatory pathways.
Still, the market commentary around Piper’s action provides limited granularity on what exactly changed versus the prior outlook, beyond pointing to the third-quarter beat and the melanoma program. Moderna did not disclose any additional specifics in the market post referenced here, so it is unclear from the available information whether the target increase was driven by new clinical data, revised probability assumptions, or changes to forecast models.
Investors and analysts will likely watch for follow-through from Moderna’s reported quarter and any subsequent communications that clarify how management sees the melanoma collaboration progressing, including the timing of upcoming milestones that could validate or undermine the raised expectations.
A sharp selloff following Intel’s third-quarter results has drawn renewed attention to Intel’s cap-structure and the government’s role as a major shareholder, turning Wall Street frustration into a broader political question about public exposure to corporate performance.
As Google rolls out additional TPU options aimed at generative AI workloads, Nvidia is likely to be judged on whether its hardware, software stack, and supply can keep winning in data centers amid heightened leadership attention.
A CNN report circulated through markets on Monday, tying a probe involving Nvidia Chief Executive Jensen Huang to allegations of a personal relationship with an alleged Chinese spy. The company’s disclosure, timing, and the scope of any investigation were not addressed in the report.
After an earnings update, Advanced Micro Devices said growth is continuing and voiced optimism for the fourth quarter, even as market attention has shifted toward concerns that the so-called AI trade is cooling.
The company is preparing a reduction of about 5% of jobs in its Commercial Airplanes division, according to a report, citing ongoing production challenges.
A new market commentary argues that the next wave of “autonomy” spending in defense may be flowing toward Shield AI, even as Palantir remains a prominent software name in military analytics.
A Yahoo Finance report says Jensen Huang’s personal ties could put Nvidia under greater scrutiny in an era where U.S. national-security concerns increasingly intersect with advanced chip supply chains.
A sharp selloff in Alphabet’s stock has erased nearly $500 billion in market value, reflecting investor skepticism about how quickly heavy AI spending will translate into profits.
Market watchers pointed to heavier-than-usual put option volume in Walmart shares as the retailer prepares to report results next week, a move that can reflect hedging or downside speculation rather than a clear directional bet.
Berkshire Hathaway repurchased $9.6 billion of its shares in the third quarter, including $3.4 billion of Class A stock, according to a Yahoo Finance report that suggests some of the A shares were acquired directly from holders.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...